title: Prostate cancer: endogenous chemical castration.
abstract: We report treatment of intermediate risk prostate cancer in a patient with a brief period of androgen deprivation secondary to a pituitary adenoma. This was a patient with intermediate risk prostate cancer diagnosed in the setting of an elevated prostate-specific antigen (PSA). The patient subsequently demonstrated a decline in PSA along with symptoms of hypogonadism and visual disturbance, and was consequently found to have a pituitary tumour. Trans-sphenoidal resection of the sellar mass was performed with normalisation of hormone profiles. The patient subsequently completed a course of radiation therapy for prostate cancer with PSA nadir to undetectable levels without evidence of biochemical recurrence at 7 months follow-up.
authors.affiliation: Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA.
authors.forename: Olugbemisola Oredein
authors.initials: OO
authors.lastname: McCoy
authors.affiliation: Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA.
authors.forename: Michaella M
authors.initials: MM
authors.lastname: Prasad
authors.affiliation: Department of Urology, Cincinnati VA Medical Center, Cincinnati, Ohio, USA.
authors.forename: Natalie
authors.initials: N
authors.lastname: Singer
mesh_terms: D000368:Aged; D006801:Humans; D007016:Hypophysectomy; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000601:surgery*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000209:etiology / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen